SEC Form 4 · accession 0001177648-18-000032
ENANTA PHARMACEUTICALS INC · ENTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jay R. Luly
Officer — President and CEO · Director
Period of report
Jul 27, 2018
Accepted (ET)
Jul 30, 2018 · 4:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001177648
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 27, 2018 | M | 8,498 | $11.7663 | A | 601,524 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $11.7663 | Jul 27, 2018 | M | 8,498 | D | — | Jun 20, 2022 | Common Stock | 8,498 | 0 | D |
Explanation of responses
- F1100% of the shares subject to the option are fully vested and exercisable.